Finding alternatives to antibiotics

Annals of the New York Academy of Sciences

Volumn 1323, Issue 1, 2014, Pages 91-100

  Allen, Heather K ^a   Trachsel, Julian ^a   Looft, Torey ^a   Casey, Thomas A ^a  

^a NATIONAL ANIMAL DISEASE CENTER   (United States)

Author keywords

Antibiotic alternatives; Antibiotic prudency; Bacteriocins; Gut microbiota; Phage therapy; Predatory bacteria

Indexed keywords

ANTIBIOTIC AGENT; POLYPEPTIDE ANTIBIOTIC AGENT; PREBIOTIC AGENT; PROBIOTIC AGENT; SYNBIOTIC AGENT; ANTIINFECTIVE AGENT; BACTERIOCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIOPHAGE; DRUG EFFICACY; ESCHERICHIA COLI; INTESTINE FLORA; KLEBSIELLA PNEUMONIAE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL COMMUNITY; NONHUMAN; PREDATOR; PSEUDOMONAS AERUGINOSA; ANIMAL; ANTIBIOTIC ALTERNATIVES; ANTIBIOTIC PRUDENCY; HUMAN; INTESTINE; MICROBIOLOGY; MICROFLORA; PHAGE THERAPY; PREDATORY BACTERIA; REVIEW;

ANTIBIOTIC ALTERNATIVES; ANTIBIOTIC PRUDENCY; BACTERIOCINS; GUT MICROBIOTA; PHAGE THERAPY; PREDATORY BACTERIA;

ANIMALS; ANTI-BACTERIAL AGENTS; HUMANS; INTESTINES; MICROBIOTA;

EID: 84907954450     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/nyas.12468     Document Type: Article

References (95)

1. Projan, S.J. & D.M. Shlaes . 2004. Antibacterial drug discovery: is it all downhill from here? Clin. Microbiol. Infect. 10(Suppl 4): 18-22.
2. Allen, H.K. et al. 2013. Treatment, promotion, commotion: antibiotic alternatives in food-producing animals. Trends Microbiol. 21: 114-119.
3. Ley, R.E., D.A. Peterson & J.I. Gordon . 2006. Ecological and evolutionary forces shaping microbial diversity in the human intestine. Cell 124: 837-848.
4. Whitman, W.B., D.C. Coleman & W.J. Wiebe . 1998. Prokaryotes: the unseen majority. Proc. Natl. Acad. Sci. USA 95: 6578-6583.
5. Zoetendal, E.G. et al. 2004. Molecular microbial ecology of the gastrointestinal tract: from phylogeny to function. Curr. Issues Intest. Microbiol. 5: 31-47.
6. Kau, A.L. et al. 2011. Human nutrition, the gut microbiome and the immune system. Nature 474: 327-336.
7. McFall-Ngai, M. et al. 2013. Animals in a bacterial world, a new imperative for the life sciences. Proc. Natl. Acad. Sci. USA 110: 3229-3236.
8. Sullivan, A., C. Edlund & C.E. Nord . 2001. Effect of antimicrobial agents on the ecological balance of human microflora. Lancet. Infect. Dis. 1: 101-114.
9. Rashid, M.U., A. Weintraub & C.E. Nord . 2012. Effect of new antimicrobial agents on the ecological balance of human microflora. Anaerobe. 18: 249-253.
10. Manichanh, C. et al. 2006. Reduced diversity of faecal microbiota in Crohn's disease revealed by a metagenomic approach. Gut 55: 205-211.
11. Ng, K.M. et al. 2013. Microbiota-liberated host sugars facilitate post-antibiotic expansion of enteric pathogens. Nature 502: 96-99.
12. Looft, T. & H.K. Allen . 2012. Collateral effects of antibiotics on mammalian gut microbiomes. Gut Microbes. 3: 463-467.
13. Ichinohe, T. et al. 2011. Microbiota regulates immune defense against respiratory tract influenza A virus infection. Proc. Natl. Acad. Sci. USA 108: 5354-5359.
14. Stecher, B., L. Maier & W.D. Hardt . 2013. 'Blooming' in the gut: how dysbiosis might contribute to pathogen evolution. Nat. Rev. Microbiol. 11: 277-284.
15. Allen, H.K. et al. 2011. Antibiotics in feed induce prophages in Swine fecal microbiomes. mBio. 2: 10.1128.
16. Lozupone, C.A. et al. 2012. Diversity, stability and resilience of the human gut microbiota. Nature 489: 220-230.
17. Shade, A. et al. 2012. Fundamentals of microbial community resistance and resilience. Front. Microbiol. 3: 417. DOI: 10.3389/fmicb.2012.00417.
18. Arumugam, M. et al. 2011. Enterotypes of the human gut microbiome. Nature 473: 174-180.
19. Fitz-Gibbon, S. et al. 2013. Propionibacterium acnes strain populations in the human skin microbiome associated with acne. J. Invest. Dermatol. 133: 2152-2160.
20. Gaggia, F., P. Mattarelli & B. Biavati . 2010. Probiotics and prebiotics in animal feeding for safe food production. Int. J. Food Microbiol. 141: S15-S28.
21. Huyghebaert, G., R. Ducatelle & F. Van Immerseel . 2011. An update on alternatives to antimicrobial growth promoters for broilers. Vet J. 187: 182-188.
22. Preidis, G.A. & J. Versalovic . 2009. Targeting the human microbiome with antibiotics, probiotics, and prebiotics: gastroenterology enters the metagenomics era. Gastroenterology 136: 2015-2031.
23. Callaway, T. et al. 2008. Probiotics, prebiotics and competitive exclusion for prophylaxis against bacterial disease. Anim. Health Res. Rev. 9: 217-225.
24. Mead, G. 2000. Prospects for 'competitive exclusion' treatment to control salmonellas and other foodborne pathogens in poultry. Vet. J. 159: 111-123.
25. Goren, E. et al. 1988. Reduction of Salmonella infection of broilers by spray application of intestinal microflora: a longitudinal study. Vet Q. 10: 249-255.
26. Vrieze, A. et al. 2013. Fecal transplant: a safe and sustainable clinical therapy for restoring intestinal microbial balance in human disease? Best Pract. Res. Clin. Gastroenterol. 27: 127-137.
27. Aroniadis, O.C. & L.J. Brandt . 2013. Fecal microbiota transplantation: past, present and future. Curr. Opin. Gastroen. 29: 79-84.
28. Borody, T.J., S. Paramsothy & G. Agrawal . 2013. Fecal microbiota transplantation: indications, methods, evidence, and future directions. Curr. Gastroenterol. Rep. 15: 337. DOI: 10.1007/s11894-013-0337-1.
29. Brandt, L.J. 2012. Fecal transplantation for the treatment of Clostridium difficile infection. Gastroenterol. Hepatol. 8: 191-194.
30. Vyas, D., E. L'Esperance H & A. Vyas . 2013. Stool therapy may become a preferred treatment of recurrent Clostridium difficile? World J. Gastroenterol. 19: 4635-4637.
31. Johnson, R.P. et al. 2008. Bacteriophages for prophylaxis and therapy in cattle, poultry and pigs. Anim. Health Res. Rev. 9: 201-215.
32. Abedon, S.T. et al. 2011. Phage treatment of human infections. Bacteriophage 1: 66-85.
33. Smith, H.W. & M.B. Huggins . 1982. Successful treatment of experimental Escherichia coli infections in mice using phage: its general superiority over antibiotics. J. Gen. Microbiol. 128: 307-318.
34. Miedzybrodzki, R. et al. 2012. Clinical aspects of phage therapy. Adv. Virus Res. 83: 73-121.
35. Biswas, B. et al. 2002. Bacteriophage therapy rescues mice bacteremic from a clinical isolate of vancomycin-resistant Enterococcus faecium. Infect Immun. 70: 204-210.
36. Chan, B.K., S.T. Abedon & C. Loc-Carrillo . 2013. Phage cocktails and the future of phage therapy. Future Microbiol. 8: 769-783.
37. Brussow, H. 2007. "Phage therapy: the western perspective." In Bacteriophage: Genetics and Microbiology. S. McGrath, Ed.: 159-192. Norfolk, UK: Caister Academic Press.
38. Goodridge, L.D. & B. Bisha . 2011. Phage-based biocontrol strategies to reduce foodborne pathogens in foods. Bacteriophage. 1: 130-137.
39. Balogh, B. et al. 2010. Phage therapy for plant disease control. Curr. Pharm. Biotechnol. 11: 48-57.
40. Koskella, B. & S. Meaden . 2013. Understanding bacteriophage specificity in natural microbial communities. Viruses 5: 806-823.
41. Koskella, B. et al. 2012. The costs of evolving resistance in heterogeneous parasite environments. Proc. R. Soc. Lond., Ser. B: Biol. Sci. 279: 1896-1903.
42. Levin, B.R. & J.J. Bull . 2004. Population and evolutionary dynamics of phage therapy. Nat. Rev. Microbiol. 2: 166-173.
43. Pirnay, J.P. et al. 2011. The phage therapy paradigm: pret-a-porter or sur-mesure? Pharm. Res. 28: 934-937.
44. Fischetti, V.A. 2008. Bacteriophage lysins as effective antibacterials. Curr. Opin. Microbiol. 11: 393-400.
45. Schmelcher, M., D.M. Donovan & M.J. Loessner . 2012. Bacteriophage endolysins as novel antimicrobials. Future Microbiol. 7: 1147-1171.
46. Fischetti, V.A. 2005. Bacteriophage lytic enzymes: novel anti-infectives. Trends Microbiol. 13: 491-496.
47. Briers, Y. et al. 2007. Muralytic activity and modular structure of the endolysins of Pseudomonas aeruginosa bacteriophages phiKZ and EL. Mol. Microbiol. 65: 1334-1344.
48. Walmagh, M. et al. 2013. Characterization of five novel endolysins from Gram-negative infecting bacteriophages. Appl. Microbiol. Biotechnol. 97: 4369-4375.
49. Lim, J.A. et al. 2012. Characterization of endolysin from a Salmonella Typhimurium-infecting bacteriophage SPN1S. Res. Microbiol. 163: 233-241.
50. Vollmer, W. et al. 2008. Bacterial peptidoglycan (murein) hydrolases. FEMS Microbiol. Rev. 32: 259-286.
51. Snyder, A.B. & R.W. Worobo . 2014. Chemical and genetic characterization of bacteriocins: antimicrobial peptides for food safety. J. Sci. Food. Agric. 94: 28-44.
52. Cotter, P.D., R.P. Ross & C. Hill . 2013. Bacteriocins-a viable alternative to antibiotics? Nat. Rev. Microbiol. 11: 95-105.
53. Vidhyasagar, V. & K. Jeevaratnam . 2013. Bacteriocin activity against various pathogens produced by Pediococcus pentosaceus VJ13 isolated from Idly batter. Biomed. Chromatogr. 27: 1497-1502.
54. Shokri, D. et al. 2013. Antimicrobial activity of a UV-stable bacteriocin-like inhibitory substance (BLIS) produced by Enterococcus faecium strain DSH20 against vancomycin-resistant Enterococcus (VRE) strains. J. Microbiol. Immunol. Infect. DOI: 10.1016/j.jmii.2013.05.004. [Jul 6. Epub ahead of print].
55. Bastos, M.d.C.d.F., B.G. Coutinho & M.L.V. Coelho . 2010. Lysostaphin: a staphylococcal bacteriolysin with potential clinical applications. Pharmaceuticals. 3: 1139-1161.
56. Zendo, T. 2013. Screening and characterization of novel bacteriocins from lactic acid bacteria. Biosci. Biotechnol. Biochem. 77: 893-899.
57. Rea, M.C. et al. 2013. Gut solutions to a gut problem: bacteriocins, probiotics and bacteriophage for control of Clostridium difficile infection. J. Med. Microbiol. 62: 1369-1378.
58. Naghmouchi, K. et al. 2011. Antibacterial activity of class I and IIa bacteriocins combined with polymyxin E against resistant variants of Listeria monocytogenes and Escherichia coli. Res. Microbiol. 162: 99-107.
59. Dwidar, M., A.K. Monnappa & R.J. Mitchell . 2012. The dual probiotic and antibiotic nature of Bdellovibrio bacteriovorus. BMB Reports 45: 71-78.
60. Lambert, C. & R.E. Sockett . 2013. Nucleases in Bdellovibrio bacteriovorus contribute towards efficient self-biofilm formation and eradication of preformed prey biofilms. FEMS Microbiol. Lett. 340: 109-116.
61. Pasternak, Z. et al. 2013. By their genes ye shall know them: genomic signatures of predatory bacteria. ISME J. 7: 756-769.
62. Costerton, J. & D. Keller . 2007. Oral periopathogens and systemic effects. Gen. Dent. 55: 210-215.
63. Sockett, E. & C. Lambert . 2004. Bdellovibrio as therapeutic agents: a predatory renaissance? Nat. Rev. Microbiol. 2: 669-674.
64. Van Essche, M. et al. 2011. Killing of anaerobic pathogens by predatory bacteria. Mol. Oral. Microbiol. 26: 52-61.
65. Kadouri, D.E., K. To, R.M.Q. Shanks & Y. Doi . 2013. Predatory bacteria: a potential ally against multidrug-resistant Gram-negative pathogens. PLoS One 8: e63397. DOI: 10.1371/journal.pone.0063397.
66. Atterbury, R.J. et al. 2011. Effects of orally administered Bdellovibrio bacteriovorus on the well-being and Salmonella colonization of young chicks. Appl. Environ. Microbiol. 77: 5794-5803.
67. Kalan, L. & G.D. Wright . 2011. Antibiotic adjuvants: multicomponent anti-infective strategies. Expert. Rev. Mol. Med. 13: e5.
68. Worthington, R.J. & C. Melander . 2013. Combination approaches to combat multidrug-resistant bacteria. Trends Biotechnol. 31: 177-184.
69. Walsh, C. 2003. Where will new antibiotics come from? Nat. Rev. Microbiol. 1: 65-70.
70. Davies, J. & D. Davies . 2010. Origins and evolution of antibiotic resistance. Microbiol. Mol. Biol. Rev. 74: 417-433.
71. Jabes, D. 2011. The antibiotic R&D pipeline: an update. Curr. Opin. Microbiol. 14: 564-569.
72. Bush, K. & M.J. Macielag . 2010. New beta-lactam antibiotics and beta-lactamase inhibitors. Expert Opin. Ther. Pat. 20: 1277-1293.
73. Bhardwaj, A.K. & P. Mohanty . 2012. Bacterial efflux pumps involved in multidrug resistance and their inhibitors: rejuvinating the antimicrobial chemotherapy. Recent Pat. Antiinfect. Drug Discov. 7: 73-89.
74. van Soolingen, D. et al. 2010. The antipsychotic thioridazine shows promising therapeutic activity in a mouse model of multidrug-resistant tuberculosis. PLoS One 5: e12640. DOI: 10.1371/journal.pone.0012640.
75. Amaral, L. et al. 2010. Thioridazine cures extensively drug-resistant tuberculosis (XDR-TB) and the need for global trials is now! Int. J. Antimicrob. Agents 35: 524-526.
76. Lin, J. & A. Martinez . 2006. Effect of efflux pump inhibitors on bile resistance and in vivo colonization of Campylobacter jejuni. J. Antimicrob. Chemother. 58: 966-972.
77. Verhue, W.M. 1978. Interaction of bacteriophage infection and low penicillin concentrations on the performance of yogurt cultures. Appl. Environ. Microbiol. 35: 1145-1149.
78. Comeau, A.M. et al. 2007. Phage-Antibiotic Synergy (PAS): beta-lactam and quinolone antibiotics stimulate virulent phage growth. PLoS One 2: e799.
79. Kohanski, M.A., M.A. DePristo & J.J. Collins . 2010. Sublethal antibiotic treatment leads to multidrug resistance via radical-induced mutagenesis. Mol. Cell. 37: 311-320.
80. Gutierrez, A. et al. 2013. β-Lactam antibiotics promote bacterial mutagenesis via an RpoS-mediated reduction in replication fidelity. Nat. Commun. 4: 1610. DOI: 10.1038/ncomms2607.
81. Ryan, E.M. et al. 2012. Synergistic phage-antibiotic combinations for the control of Escherichia coli biofilms in vitro. FEMS Immunol. Med. Microbiol. 65: 395-398.
82. Kaur, S., K. Harjai & S. Chhibber . 2012. Methicillin-resistant Staphylococcus aureus phage plaque size enhancement using sublethal concentrations of antibiotics. Appl. Environ. Microbiol. 78: 8227-8233.
83. Knezevic, P. et al. 2012. Phage-antibiotic synergism: a possible approach to combatting Pseudomonas aeruginosa. Res. Microbiol. 164: 55-60.
84. Djurkovic, S., J.M. Loeffler & V.A. Fischetti . 2005. Synergistic killing of Streptococcus pneumoniae with the bacteriophage lytic enzyme Cpl-1 and penicillin or gentamicin depends on the level of penicillin resistance. Antimicrob. Agents Chemother. 49: 1225-1228.
85. Zhang, Q.G. & A. Buckling . 2012. Phages limit the evolution of bacterial antibiotic resistance in experimental microcosms. Evol. Appl. 5: 575-582.
86. Biswas, S. et al. 2012. Colistin: an update on the antibiotic of the 21st century. Expert Rev. Anti-Infective Ther. 10: 917-934.
87. Naghmouchi, K. et al. 2013. Synergistic effect between colistin and bacteriocins in controlling Gram-negative pathogens and their potential to reduce antibiotic toxicity in mammalian epithelial cells. Antimicrob Agents Chemother. 57: 2719-2725.
88. Luders, T. et al. 2003. Strong synergy between a eukaryotic antimicrobial peptide and bacteriocins from lactic acid bacteria. Appl. Environ. Microbiol. 69: 1797-1799.
89. Naghmouchi, K. et al. 2010. Nisin A and polymyxin B as synergistic inhibitors of Gram-positive and Gram-negative bacteria. Probio. Antimicrob. Proteins. 2: 98-103.
90. Nyquist, A.C. et al. 1998. Antibiotic prescribing for children with colds, upper respiratory tract infections, and bronchitis. JAMA 279: 875-877.
91. Gonzales, R., J.F. Steiner & M.A. Sande . 1997. Antibiotic prescribing for adults with colds, upper respiratory tract infections, and bronchitis by ambulatory care physicians. JAMA 278: 901-904.
92. van Panhuis, W.G. et al. 2013. Contagious diseases in the United States from 1888 to the present. New Engl. J. Med. 369: 2152-2158.
93. Mishra, R.P. et al. 2012. Vaccines and antibiotic resistance. Curr. Opin. Microbiol. 15: 596-602.
94. Meropol, S.B., A.R. Localio & J.P. Metlay . 2013. Risks and benefits associated with antibiotic use for acute respiratory infections: a cohort study. Ann. Fam. Med. 11: 165-172.
95. National Animal Health Monitoring System. 2006. Reference of swine health and health management practices in the United States, Part II. 1-79.